Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark Office
Jan 28, 2022
Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology
Jan 18, 2022
Nutriband Inc. And Kindeva Drug Delivery Sign Feasibility Agreement to Develop AVERSA(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
Jan 10, 2022
Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm
Jan 5, 2022
Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its "Abuse and Misuse Deterrent Transdermal System" Application
Dec 31, 2021
Nutriband Inc. Announces $1 Million Share Repurchase Authorization
Dec 29, 2021
Nutriband Inc. Initiates Plans to Offer Topical Lotion Contract Manufacturing Services
Dec 21, 2021
Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary
Dec 13, 2021
Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021
Dec 3, 2021
Nutriband Inc. Initiates Commercial Development of Lead Product AVERSA(TM) Fentanyl
Nov 16, 2021